InterMune (nasdaq)ITMN Message Board

To: Biomaven who wrote (488)

5/16/2012 10:09:01 AM

of 500

This issue of potential side effects came to mind when I saw the view from PK-PD modeling that higher dose could be used to display higher efficacy. I agree that in fatal diseases being treated in older adults, like IPF, this should be less of an issue.

Jim